TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26404337

Group type: EXPERIMENTAL
Intervention: Improved water supply in intervention communities
Number of subjects: 607

Group type: COMPARATOR
Intervention: Control communities with no intervention
Number of subjects: 607
Study: 24777970

Group type: COMPARATOR
Intervention: OLP alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: OLP in Montanide
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: OLP and poly-ICLC in Montanide
Number of subjects: 12
Study: 21321613

Group type: EXPERIMENTAL
Intervention: Oral rinse of Turkish gall
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional oral hygiene only (Control)
Number of subjects: 70
Study: 18727139

Group type: EXPERIMENTAL
Intervention: Single session educational intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 17485971

Group type: EXPERIMENTAL
Intervention: Amlodipine + Valsartan combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amlodipine (2.5 or 5 mg/d; 10 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Valsartan (40, 80, 160, or 320 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15460635

Group type: EXPERIMENTAL
Intervention: Hypoxic gas mixture (F(IO)2 = 12.2%, equivalent to 4000 m)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normoxic room air (F(IO)2 = 20.9%)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hypoxic gas mixture (F(IO)2 = 12.2%)
Number of subjects: 16
Study: 11437015

Group type: EXPERIMENTAL
Intervention: Fluoxetine (10 mg daily for 2 weeks, then increased to 20 mg daily, with possible increase to 60 mg daily)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 10220010

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control subjects (healthy subjects)
Number of subjects: 46
Study: 7541003

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Nd:YAG laser therapy
Number of subjects: 52
Study: 2150533

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure recordings
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Office blood pressure recordings
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Untreated hypertensives with randomly allocated treatment
Number of subjects: 2000
Study: 480560

Group type: EXPERIMENTAL
Intervention: Iridology
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 143
Study: 31691002

Group type: COMPARATOR
Intervention: Lower socioeconomic position (SEP)
Number of subjects: 4787

Group type: COMPARATOR
Intervention: Current smoking and low fruit consumption
Number of subjects: 4787

Group type: COMPARATOR
Intervention: Potential mediating risk factors (body mass index, diabetes, smoking, dietary factors)
Number of subjects: 4787
Study: 28165768

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BTJ)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Isocaloric placebo (PLA)
Number of subjects: 34
Study: 25848938

Group type: COMPARATOR
Intervention: Area-level Index of Multiple Deprivation (IMD) 2007
Number of subjects: 50029

Group type: COMPARATOR
Intervention: Education level
Number of subjects: 50029
Study: 23422374

Group type: EXPERIMENTAL
Intervention: Paliperidone starting dose of 3 mg/d; subsequent dosing range of 3 to 6 mg/d for adolescents less than 51 kg and 3 to 12 mg/d for adolescents greater than or equal to 51 kg.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paliperidone
Number of subjects: 0
Study: 21552707

Group type: EXPERIMENTAL
Intervention: Triclosan mouthrinse
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Essential oil mouthrinse
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Enzymatic solution
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cetilpiridine chloride associated with sodium chloride mouthrinse
Number of subjects: 50

Group type: COMPARATOR
Intervention: Distilled water mouthrinse
Number of subjects: 50
Study: 19856793

Group type: EXPERIMENTAL
Intervention: Isoxsuprine hydrochloride 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoxsuprine hydrochloride 60 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoxsuprine hydrochloride 90 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isoxsuprine hydrochloride 10 mg (i.m. route)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both oral and i.m. routes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All four administrations of isoxsuprine
Number of subjects: 0
Study: 18705933

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (aspirin, dipyridamole or clopidogrel alone or in dual combination)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Anticoagulation therapy (heparin followed by warfarin aiming for an INR in the range 2-3)
Number of subjects: 250
Study: 15141368

Group type: EXPERIMENTAL
Intervention: Counseling and nicotine replacement therapy
Number of subjects: 237

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 237
Study: 11826694

Group type: EXPERIMENTAL
Intervention: Mygind position
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ragan position
Number of subjects: 5

Group type: COMPARATOR
Intervention: Mecca position
Number of subjects: 5

Group type: COMPARATOR
Intervention: Head back position
Number of subjects: 5
Study: 11736715

Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg twice daily) and Ethambutol (15 mg/kg daily) for 3 months
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 31
Study: 9264222

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (Gamimune-N, Miles Pharmaceutical Co) 200 mg/kg monthly for 1 year
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (indeterminate patients with no evidence of infection)
Number of subjects: 135
Study: 8518774

Group type: EXPERIMENTAL
Intervention: Theophylline (Uniphyllin Continus tablets) at a mean steady-state plasma level of 14 mg.l-1
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 3501750

Group type: EXPERIMENTAL
Intervention: Ofloxacin 100mg twice daily for 3 days
Number of subjects: 250

Group type: COMPARATOR
Intervention: Trimethoprim-sulphamethoxazole 160mg + 800mg twice daily for 3 days
Number of subjects: 250
Study: 2403756

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy regimens containing Adriamycin (doxorubicin) and mitomycin-C
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive care only
Number of subjects: 0
Study: 30718168

Group type: EXPERIMENTAL
Intervention: Dynamic hallux valgus splint
Number of subjects: 70

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 70
Study: 31503181

Group type: EXPERIMENTAL
Intervention: Good‐outcome group
Number of subjects: 18

Group type: COMPARATOR
Intervention: Poor‐outcome group
Number of subjects: 18
Study: 29248944

Group type: EXPERIMENTAL
Intervention: Amelogen Plus TW, Ultradent Products Inc.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Filtek Z350 XT, 3MESPE
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 40
Study: 25556355

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with zoledronic acid
Number of subjects: 38

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy without zoledronic acid
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 38
Study: 23188217

Group type: EXPERIMENTAL
Intervention: Crural closure followed by fundoplication (group 1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fundoplication followed by crural closure (group 2)
Number of subjects: 18
Study: 20882668

Group type: EXPERIMENTAL
Intervention: Active intraoral electrostimulation device
Number of subjects: 114

Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 114
Study: 19615303

Group type: EXPERIMENTAL
Intervention: Biofeedback therapy for dyssynergic defecation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Management including education, counseling, diet, laxatives, and behavioral therapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical approaches (e.g., stapled transanal rectal resection)
Number of subjects: 0
Study: 17256140

Group type: EXPERIMENTAL
Intervention: 123I diagnostic scans
Number of subjects: 292

Group type: COMPARATOR
Intervention: Post-treatment 131I scans
Number of subjects: 292

Group type: COMPARATOR
Intervention: Negative diagnostic 123I scans
Number of subjects: 292

Group type: COMPARATOR
Intervention: Pre- and post-treatment scans
Number of subjects: 292
Study: 15083754

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP; 1,000 micrograms)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 12530554

Group type: EXPERIMENTAL
Intervention: LCP-supplemented formula
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (nonsupplemented formula)
Number of subjects: 23
Study: 9667348

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 175

Group type: COMPARATOR
Intervention: Ondansetron 0.5 mg
Number of subjects: 175

Group type: COMPARATOR
Intervention: Ondansetron 1 mg
Number of subjects: 175

Group type: COMPARATOR
Intervention: Ondansetron 2 mg
Number of subjects: 175

Group type: COMPARATOR
Intervention: Ondansetron 8 mg
Number of subjects: 175

Group type: COMPARATOR
Intervention: Ondansetron 16 mg
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: All doses of ondansetron
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Nausea scores
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Patient satisfaction via VAS
Number of subjects: 175
Study: 7536263

Group type: EXPERIMENTAL
Intervention: Systematic removal of catheter 24 hours after transurethral incision (group 1 - 52 patients)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Systematic removal of catheter 48 hours after transurethral resection (group 1 - 54 patients)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control group with catheterization interval determined by surgeon (group 2 - 52 patients)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control group with catheterization interval determined by surgeon (group 2 - 55 patients)
Number of subjects: 213
Study: 2719233

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 122

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 122
Study: 197982

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nicotinic acid
Number of subjects: 10
Study: 31486399

Group type: EXPERIMENTAL
Intervention: Cellulose biomembrane
Number of subjects: 46

Group type: COMPARATOR
Intervention: Collagenase dressing
Number of subjects: 46
Study: 26051565

Group type: EXPERIMENTAL
Intervention: Curcumin (two capsules daily for seven days before menstruation and for three days after menstruation for three successive cycles)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (two capsules daily for seven days before menstruation and for three days after menstruation for three successive cycles)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Curcumin vs Placebo
Number of subjects: 70
Study: 23182405

Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 30 (BIAsp 30)
Number of subjects: 52419

Group type: EXPERIMENTAL
Intervention: BIAsp 30
Number of subjects: 52419
Study: 21054553

Group type: EXPERIMENTAL
Intervention: Mallet osteotomes (Group 1, n=98)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Screwable osteotomes (Group 2, n=98)
Number of subjects: 196
Study: 18820592

Group type: EXPERIMENTAL
Intervention: 25 microg estradiol (Vagifem)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1 g (0.625 mg) conjugated estrogens (Premarin cream)
Number of subjects: 20
Study: 17990769

Group type: EXPERIMENTAL
Intervention: Navigated group (11 patients, 13 hips) treated by THA using the non-image based surgical navigation system
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (12 patients, 13 hips) treated by traditional THA
Number of subjects: 23
Study: 15587240

Group type: EXPERIMENTAL
Intervention: Lavender scent
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Rosemary scent
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control (water scent)
Number of subjects: 73
Study: 11307048

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 9533262

Group type: EXPERIMENTAL
Intervention: Bayesian estimation methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-Bayesian estimation methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fully-parametric methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semi-parametric methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonparametric methods
Number of subjects: 0
Study: 8033428

Group type: EXPERIMENTAL
Intervention: 500 mg/kg IVIG every 4 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: 250 mg/kg IVIG every 4 weeks
Number of subjects: 36
Study: 2672385

Group type: EXPERIMENTAL
Intervention: Single dose piperacillin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multidose cefoxitin
Number of subjects: 0
Study: 30508206

Group type: EXPERIMENTAL
Intervention: Autonomous style
Number of subjects: 251

Group type: COMPARATOR
Intervention: Paternalistic style
Number of subjects: 251
Study: 29332430

Group type: EXPERIMENTAL
Intervention: Creatine phosphate sodium (1.0 g/100 ml 0.9% saline)
Number of subjects: 120

Group type: COMPARATOR
Intervention: 100 ml 0.9% saline (control)
Number of subjects: 120
Study: 26818484

Group type: EXPERIMENTAL
Intervention: Multi-faceted systems-based package to improve penicillin delivery, aligned with elements of the Chronic Care Model, with continuous quality improvement processes including 3-monthly feedback to clinic staff.
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Multi-faceted systems-based package to improve penicillin delivery, aligned with elements of the Chronic Care Model.
Number of subjects: 300
Study: 24325931

Group type: EXPERIMENTAL
Intervention: Distal embolic protection devices (n = 161)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Nonuse of distal embolic protection devices (n = 78)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Renal artery stent placement
Number of subjects: 239
Study: 22121130

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) plus methotrexate (MTX)
Number of subjects: 531

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 531
Study: 20635776

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 17618764

Group type: EXPERIMENTAL
Intervention: Clean Intermittent Self-Catheterization (CISC)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Suprapubic Catheterization (SPC)
Number of subjects: 210
Study: 15115243

Group type: EXPERIMENTAL
Intervention: Hyperoxia (FiO2 of 1.0 for 20 min)
Number of subjects: 8
Study: 11591493

Group type: EXPERIMENTAL
Intervention: Nicotine (transdermal administration)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9715571

Group type: EXPERIMENTAL
Intervention: Sinus grafts with implants
Number of subjects: 1007

Group type: COMPARATOR
Intervention: Various grafting materials and implant surfaces
Number of subjects: 1007
Study: 7672877

Group type: EXPERIMENTAL
Intervention: Etodolac SR 600 mg u.i.d. for 8 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Tenoxicam 20 mg u.i.d. for 8 weeks
Number of subjects: 120
Study: 2609944

Group type: EXPERIMENTAL
Intervention: Chlorhexidine acetate in periodontal dressing
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control dressings (without chlorhexidine)
Number of subjects: 11
Study: 31969175

Group type: EXPERIMENTAL
Intervention: Active de-implementation strategy for reducing low-value pharmacological prescribing of statins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual procedures for dissemination of clinical practice guidelines (control)
Number of subjects: 0
Study: 31092043

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) with dual-site stimulation over the auditory temporal and frontal regions (TF group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation (rTMS) with single-site stimulation over the auditory temporal cortex (T group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation (S group)
Number of subjects: 0
Study: 27260764

Group type: EXPERIMENTAL
Intervention: Pilates exercise program (n=27)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (leaflet information, n=27)
Number of subjects: 54
Study: 26567256

Group type: EXPERIMENTAL
Intervention: Informed shared decision-making programme (ISDM-P)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control intervention (sham)
Number of subjects: 154
Study: 23652896

Group type: EXPERIMENTAL
Intervention: Topical antioxidant complex containing vitamins C and E and ferulic acid
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Untreated site (positive control)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Negative control (no treatment)
Number of subjects: 12
Study: 20175775

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 18619791

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Antibiotic treatment
Number of subjects: 100
Study: 15935538

Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 128

Group type: COMPARATOR
Intervention: Females
Number of subjects: 128
Study: 12814453

Group type: EXPERIMENTAL
Intervention: Nafcillin 500 mg four times daily for 5 days
Number of subjects: 9

Group type: COMPARATOR
Intervention: Nifedipine 10 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nafcillin pretreatment
Number of subjects: 9

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 9
Study: 10996104

Group type: EXPERIMENTAL
Intervention: Mechanical valves
Number of subjects: 1229

Group type: EXPERIMENTAL
Intervention: Bioprosthesis
Number of subjects: 1229

Group type: COMPARATOR
Intervention: Valve type (Mechanical vs Bioprosthesis)
Number of subjects: 1229
Study: 8795732

Group type: EXPERIMENTAL
Intervention: Acetazolamide (1,000 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CO2 (6% CO2, 94% O2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acetazolamide + CO2
Number of subjects: 12

Group type: COMPARATOR
Intervention: Acetazolamide
Number of subjects: 12

Group type: COMPARATOR
Intervention: CO2
Number of subjects: 12
Study: 8320924

Group type: EXPERIMENTAL
Intervention: Cuprophane membrane hemodialysis
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: AN69 membrane hemodialysis
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 10
Study: 3711365

Group type: EXPERIMENTAL
Intervention: lithium + sulindac (300 mg/day)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: lithium + naproxen (750 mg/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: lithium alone
Number of subjects: 13
Study: 30541220

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 60
Study: 25831599

Group type: EXPERIMENTAL
Intervention: Oscillating-rotating power toothbrush with angled CrissCross bristles (Oral-B Pro 7000 SmartSeries and Oral-B CrossAction brush head)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Marketed sonic toothbrush (Colgate ProClinical A1500 with the Triple Clean brush head)
Number of subjects: 130
Study: 22738715

Group type: EXPERIMENTAL
Intervention: Web CBT plus weekly telephone tracking
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Web CBT only
Number of subjects: 155

Group type: COMPARATOR
Intervention: Weekly telephone tracking only
Number of subjects: 155

Group type: COMPARATOR
Intervention: Neither Web CBT nor telephone tracking
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Web-only condition
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Web plus tracking conditions
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Web-only and Web plus tracking conditions
Number of subjects: 155
Study: 19799592

Group type: EXPERIMENTAL
Intervention: Dorzolamide 2% (DT) added to timolol 0.5%
Number of subjects: 161

Group type: COMPARATOR
Intervention: Brinzolamide 1% (BT) added to timolol 0.5%
Number of subjects: 161
Study: 18613992

Group type: EXPERIMENTAL
Intervention: Alternative treatment group (lifestyle changes, red yeast rice, and fish oil)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Simvastatin (40 mg/d)
Number of subjects: 74
Study: 16150503

Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy (RT)
Number of subjects: 1538

Group type: EXPERIMENTAL
Intervention: Megavoltage RT
Number of subjects: 1538
Study: 11927123

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (dalteparin)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 10713867

Group type: EXPERIMENTAL
Intervention: Remifentanil (group R)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Propofol (group P)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combination of Remifentanil and Propofol (group RP)
Number of subjects: 45
Study: 7604788

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 57
Study: 2379228

Group type: EXPERIMENTAL
Intervention: Clindamycin 300 mg orally thrice daily for seven days
Number of subjects: 61

Group type: COMPARATOR
Intervention: Cloxacillin 500 mg orally thrice daily for seven days
Number of subjects: 61
Study: 102115

Group type: EXPERIMENTAL
Intervention: Chlorimipramine 25 mg t.i.d.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nortriptyline 25 mg t.i.d.
Number of subjects: 6

Group type: COMPARATOR
Intervention: TRH 200 microgram i.v. stimulation
Number of subjects: 6
Study: 30316719

Group type: EXPERIMENTAL
Intervention: Cephalad‐caudad blunt expansion of uterine incision
Number of subjects: 839

Group type: COMPARATOR
Intervention: Transverse (lateral‐lateral) expansion
Number of subjects: 839